MedTech Business - November 6, 2025
Mölnlycke establishes first wound care manufacturing site in China
The manufacturing site, spanning 10,000 m2 is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027.
New Market - November 5, 2025
Moberg Pharma and Karo Healthcare in license agreement
Moberg Pharma has entered into an exclusive licensing agreement with Karo Healthcare regarding the commercialization of MOB-015 (Terclara) in Europe.
Biotech Business - October 14, 2025
First patient treated with BioArctic’s Leqembi in the Nordics
Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment.
Biotech Business - September 22, 2025
Alvotech receives 3 marketing approvals in Japan
Alvotech has announced that its commercialization partner in Japan, Fuji Pharma, has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare.
Agreement - September 17, 2025
ALK enters partnership with GenSci
ALK has announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical to develop and commercialize ALK’s house dust mite allergy immunotherapy (AIT) products in Mainland China.
Biotech Business - August 25, 2025
Leqembi launched in the EU – Austria and Germany will mark the first launches
BioArctic's partner Eisai has announced that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025.
